Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NLS Pharmaceutics ( (NLSP) ) just unveiled an announcement.
On October 28, 2025, NLS Pharmaceutics and Kadimastem announced the completion of all material conditions for their merger, with the closing date set for October 30, 2025. Following the merger, Kadimastem’s shares will be delisted from the Tel Aviv Stock Exchange, and the combined company, NewCelX Ltd., will be listed on the Nasdaq Capital Market under the ticker ‘NCEL’.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company that focuses on developing innovative therapies for central nervous system disorders. Kadimastem Ltd. is a clinical-stage cell therapy company that develops allogeneic cell products for neurodegenerative diseases and diabetes.
Average Trading Volume: 658,465
Technical Sentiment Signal: Sell
Current Market Cap: $5.53M
For a thorough assessment of NLSP stock, go to TipRanks’ Stock Analysis page.